Canadian National Breast Screening Study
The Canadian National Breast Screening Study (CNBSS) was a randomized controlled trial designed to evaluate the effectiveness of breast cancer screening in reducing mortality. Initiated in 1980 and concluding its initial phase in 1985, the study enrolled 89,835 women aged 40 to 59 across Canada. It aimed to assess the impact of mammography and physical examination of the breasts in detecting breast cancer early and improving survival rates.
Background[edit | edit source]
Breast cancer is a leading cause of death among women worldwide. Early detection through screening is believed to reduce mortality rates. The CNBSS was developed in response to growing demand for scientific evidence supporting the effectiveness of breast cancer screening programs.
Methodology[edit | edit source]
Participants were randomly assigned to two groups: the screening group, which received annual mammography and physical examinations, and the control group, which received only usual care without specific screening. The study's primary endpoint was breast cancer mortality.
Findings[edit | edit source]
The CNBSS published its results in several phases, with key findings indicating that there was no significant difference in breast cancer mortality between the screened group and the control group after a follow-up period of up to 25 years. These results sparked significant debate within the medical community regarding the benefits of routine mammographic screening.
Controversies[edit | edit source]
The CNBSS faced criticism for various aspects of its methodology, including the randomization process, the quality of mammography, and the handling of screen-detected lesions. Critics argued that these factors might have influenced the study's findings.
Impact[edit | edit source]
Despite the controversies, the CNBSS has had a significant impact on breast cancer screening policies and practices. It has contributed to the ongoing debate about the age at which screening should start and the frequency of screening. The study's long-term follow-up continues to provide valuable data for understanding the complexities of breast cancer screening.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
